国联医药消费混合A连续5个交易日下跌，区间累计跌幅7.36%

Core Insights - Guolian Pharmaceutical Consumption Mixed A (015032) has experienced a decline of 1.35% on June 19, with a latest net value of 0.9 yuan, marking a cumulative drop of 7.36% over five consecutive trading days [1] - The fund was established in March 2022 with a total size of 0.28 billion yuan and has recorded a cumulative return of -9.51% since inception [1] - As of the end of 2024, institutional investors hold 0.04 billion shares, accounting for 12.38% of total shares, while individual investors hold 0.32 billion shares, making up 87.62% of total shares [1] Fund Manager Profile - The current fund manager, Mr. Pan Tianqi, holds a Bachelor of Science from Sichuan University, a Master of Science from the University of Pittsburgh, and an MBA from Katz Graduate School of Business [1] - Mr. Pan has previously worked as a researcher at Heng Rui Medicine Co., Ltd., and as a senior researcher and assistant fund manager at Guotai Junan Fund Management Co., Ltd. [1] - He joined He Xu Zhi Yuan Fund Management Co., Ltd. in July 2018 and has held various managerial positions, including the fund manager of the Zhongrong Pharmaceutical Consumption Mixed Securities Investment Fund since June 14, 2022 [1] Top Holdings - As of March 31, 2025, the top ten holdings of Guolian Pharmaceutical Consumption Mixed A account for a total of 48.85%, with significant positions in Heng Rui Medicine (7.78%), Zai Lab (6.18%), and BeiGene (4.69%) [2] - Other notable holdings include Haoyuan Pharmaceutical (4.50%), Aosaikang (4.45%), and Nocera Health (4.36%) [2] - The fund also holds shares in Guizhou Moutai (4.35%), Dize Pharmaceutical (4.31%), Yifang Bio (4.25%), and United Imaging Healthcare (3.98%) [2]